Trump announces trade deal with EU following months of negotiations
SLOUGH, UK – Indivior PLC (NASDAQ/LSE: LON:INDV), a global pharmaceutical company specializing in the treatment of substance use disorders (SUD), will unveil its fourth quarter and full-year 2024 financial results on February 20th, according to a statement released today. The announcement is scheduled for 7:00 a.m. London time, with the results being disseminated through the Regulatory News Service of the London Stock Exchange (LON:LSEG) and on Indivior’s website.
Following the release, CEO Mark Crossley and the leadership team will conduct a live webcast presentation at 1:00 p.m. London time. Interested parties can access the webcast on the company’s website, and participants have the option to join the presentation via a telephone call by registering online beforehand. A replay of the presentation will also be available on the company’s website for those unable to attend the live event.
Indivior, headquartered in Richmond, VA, is committed to addressing the challenges of SUD and transforming it from a global crisis into a recognized and treatable chronic disease. The company employs over 1,000 individuals and markets its portfolio of treatments in more than 30 countries.
This upcoming financial disclosure follows Indivior’s ongoing efforts to expand its portfolio and develop new treatments for opioid use disorder (OUD) and other substance-related conditions. The results will provide investors and stakeholders with insights into the company’s performance and strategic direction.
The information for this article is based on a press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.